Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard of care for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) with common mutations (Del19 or L858R); however, 7%-23% of NSCLC tumors harbor uncommon EGFR mutations. These mutations...

Full description

Bibliographic Details
Main Authors: Ahn, H.K (Author), Daoud, H. (Author), Hsia, T.-C (Author), Hung, J.-Y (Author), Jung, H.A (Author), Lee, S.H (Author), Lee, S.S (Author), Lee, Y.C (Author), Märten, A. (Author), Mascaux, C. (Author), Miura, S. (Author), Okamoto, T. (Author), Park, C.K (Author), Popat, S. (Author), Sato, Y. (Author), Shih, J.-Y (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
afatinib
aged
Aged
Carcinoma, Non-Small-Cell Lung
clinical trial
cohort analysis
Cohort Studies
EGFR
EGFR protein, human
epidermal growth factor receptor
ErbB Receptors
erlotinib
gefitinib
genetics
human
Humans
Lung Neoplasms
lung tumor
multicenter study
mutation
Mutation
non small cell lung cancer
osimertinib
pathology
protein kinase inhibitor
Protein Kinase Inhibitors
Retrospective Studies
retrospective study
uncommon EGFR mutations
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items